All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08]
COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.02; 49.67]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
0.71 [0.25 ; 2.02 ] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID-PEP-Post exposure (Boulware), 2020, PATCH-cohort 3 PreP (Abella), 2020 3 0% 3,450 moderate not evaluable hospitalizationdetailed results COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.06; 15.77]
Rojas-Serrano, 2021 1.05 [0.02; 53.69]
1.00 [0.10 ; 9.70 ] COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 2021 2 0% 948 low not evaluable symptomatic Covid-19detailed results Barnabas RV, 2020 1.27 [0.79; 2.04]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.65 [0.18; 2.33]
COVID PREP HCQ (2x week, Rajasingham), 2020 1.18 [0.40; 3.50]
COVID-PEP-Post exposure (Boulware), 2020 0.84 [0.55; 1.27]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
0.89 [0.68 ; 1.17 ] Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, HERO-HCQ (Naggie), 2021, Rojas-Serrano, 2021 6 14% 5,113 low not evaluable asymptomatic COVID casedetailed results EPICOS (Polo), 2022 0.96 [0.49; 1.90]
0.96 [0.49 ; 1.90 ] EPICOS (Polo), 2022 1 0% 454 NA not evaluable infection (PCR positive symptomatic or not)detailed results Barnabas RV, 2020 1.10 [0.73; 1.66]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.73 [0.45; 1.19]
COVID PREP HCQ (2x week, Rajasingham), 2020 0.74 [0.45; 1.21]
COVID-PEP-Post exposure (Boulware), 2020 1.21 [0.49; 2.94]
EPICOS (Polo), 2022 0.87 [0.47; 1.62]
HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15]
PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98]
Rojas-Serrano, 2021 0.16 [0.02; 1.38]
0.85 [0.70 ; 1.02 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, EPICOS (Polo), 2022, HERO-HCQ (Naggie), 2021, PATCH-cohort 3 PreP (Abella), 2020, Rojas-Serrano, 2021 9 0% 5,692 low not evaluable serious adverse eventsdetailed results Barnabas RV, 2020 1.04 [0.15; 7.40]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82]
PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16]
0.91 [0.47 ; 1.76 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, PATCH-cohort 3 PreP (Abella), 2020 3 0% 3,458 moderate not evaluable adverse eventsdetailed results Barnabas RV, 2020 1.58 [1.06; 2.37]
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20]
COVID PREP (HCQ 1x week, Rajasingham), 2020 0.59 [0.44; 0.79]
COVID PREP HCQ (2x week, Rajasingham), 2020 2.02 [1.52; 2.70]
COVID-PEP-Post exposure (Boulware), 2020 3.32 [2.33; 4.72]
Rojas-Serrano, 2021 1.64 [0.78; 3.42]
2.45 [0.77 ; 7.81 ] Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 2021 6 99% 6,130 low not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 08:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290